Biogen Pharmachem Industries
BSE: 531752
₹ 0.25▲ 0.01 (+4.17%)28 Oct, 03:29 pm IST
- Market cap
- ₹ 24 Cr.
- P/E
- 32.1x
- P/B
- 0.26x
- 52-week range
- 0.23 – 0.72
- ROE
- 1%
- ROCE
- 1%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Finance
- Industry
- Other Financial Services
- Listed on
- BSE
About
Biogen Pharmachem Industries Limited is an India-based company, which is not engaged in any activity. The Company is looking for the right opportunity to make the Company operational.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Other Financial Services: 120 companies →Biogen Pharmachem Industries against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)32.1 against a typical 30.9: pricier than most peers (1st = cheapest).61st of 119
- Profit growth−83.6% against a typical −1.6% from a year earlier.63rd of 85
- Share price, 3 months−13.8% against a typical −4.8%.68th of 97
- Size₹ 24.4 Cr. market value against a typical ₹ 35.5 Cr. (1st = largest).67th of 113
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1 | −0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating Profit | −0 | −0 | 1 | −0 | −0 | −1 | 1 | −0 | −0 | 0 | −0 | 0 |
| OPM % | — | — | 94.9% | — | — | — | 87.4% | — | — | 85.2% | −62.1% | 50% |
| Other Income | 1 | 0 | 0 | 0 | −1 | 0 | 0 | 2 | −0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 0 | 1 | −0 | −1 | −0 | 1 | 1 | −0 | 0 | −0 | 0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 1 | 0 | 1 | −0 | −1 | −0 | 1 | 1 | −0 | 0 | −0 | 0 |
| EPS in Rs | 0.01 | 0 | 0.01 | 0 | −0.01 | 0 | 0.02 | 0.01 | 0 | 0 | 0 | 0 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- 10%
- 3 Years
- —
- TTM
- 16%
Compounded Profit Growth
- 10 Years
- 41%
- 5 Years
- 20%
- 3 Years
- 85%
- TTM
- −114%
Stock Price CAGR
- 10 Years
- 5%
- 5 Years
- −16%
- 3 Years
- −26%
- TTM
- —
Return on Equity
- 10 Years
- −1%
- 5 Years
- 1%
- 3 Years
- 1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 32.1xEPS (12 months) ₹ 0.01Median P/E 68.4x
P/E (times)EPS (₹)
Peers
Listed companies in the same business.
| Biogen Pharmachem Industries | ₹ 0.25 | ₹ 24 Cr. | 32.1x | 0.3x | 1% | — |
| ICICI Prudential Asset Management Company Ltd | ₹ 2,655.00 | ₹ 1,30,928 Cr. | 47.7x | 37.7x | — | 56% |
| HDFC Asset Management Company | ₹ 2,250.00 | ₹ 96,542 Cr. | 39.9x | 12.3x | — | 69.3% |
| Nippon Life India Asset Management | ₹ 922.10 | ₹ 59,010 Cr. | 50.1x | 16.3x | 34.5% | 56.4% |
| Multi Commodity Exchange Of India | ₹ 3,017.00 | ₹ 76,931 Cr. | 52.6x | 16.6x | 37.9% | 57.8% |
| Motilal Oswal Financial Services | ₹ 925.00 | ₹ 55,715 Cr. | 30.8x | 4.5x | 15.6% | 21.2% |
Management
- Akshay Makadiya
- Chief Financial Officer, Executive Director
- Girishbhai Gatubhai Doshi
- Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.